Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype.

We have used genomic probes which specifically recognize DNA rearrangements of the RAR-alpha locus on chromosome 17q21 in patients with acute promyelocytic leukaemia (APL) and acute myeloid leukaemia (AML) subtypes. Molecular data were examined in comparison with morphological and immunophenotypic characterization at diagnosis in 20 hypergranular FAB M3 cases, five microgranular APL (M3v), 51 non-M3 AML and 12 myeloid CML blast crises. Rearrangements of the RAR-alpha locus were only detected in 23/25 APL cases and in none of the other FAB subtypes analysed. Surface marker characterization showed a consistent immunophenotypic profile--HLADR negative, CD9 and CD13/33 positive--in all M3 and M3v cases. Neither HLADR negativity nor CD9 positivity were associated with RAR-alpha rearrangements in non M3 AML. Our data indicate that RAR-alpha gene rearrangements are relevant diagnostic features of both M3 and M3v, and may prove useful molecular marker for follow-up analysis in APL patients.

[1]  Z A Arlin,et al.  Treatment of acute promyelocytic leukemia. , 1992, Blood.

[2]  A. Dejean,et al.  The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. , 1990, Leukemia.

[3]  P. Pandolfi,et al.  Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias , 1990, The Journal of experimental medicine.

[4]  R. Mayer,et al.  The unique aspects of acute promyelocytic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[6]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[7]  D. Sheer,et al.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. , 1990, Science.

[8]  F. Mandelli,et al.  Immunological definition of acute promyelocyte leukemia (FAB M3): A study of 39 cases , 1990, European journal of haematology.

[9]  F. Mandelli,et al.  Idarubicin (4‐demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA , 1990, European journal of haematology.

[10]  V. Štolc,et al.  Microgranular promyelocytic leukemia: A multiparameter examination , 1989, American journal of hematology.

[11]  H. Zola,et al.  Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification , 1986, British journal of haematology.

[12]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[13]  R. Berger,et al.  Cytological types of mitoses and chromosome abnormalities in acute leukemia. , 1983, Leukemia research.

[14]  J. Rowley,et al.  "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. , 1980, Blood.

[15]  H. Gralnick,et al.  A VARIANT FORM OF HYPERGRANULAR PROMYELOCYTIC LEUKAEMIA (M3) , 1980, British journal of haematology.

[16]  J. Rowley,et al.  15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1977, The Lancet.

[17]  M. Boiron,et al.  Acute promyelocytic leukemia: results of treatment by daunorubicin. , 1973, Blood.